Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Earnings for Jaguar Health, Inc. (JAGX)
Earnings in 2023 (TTM): $-41,901,000
According to Jaguar Health, Inc.'s latest financial reports the company's current earnings (TTM) are $-41,901,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Jaguar Health, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-41,901,000 | $-41,300,000 |
| 2022 | $-48,395,000 | $-47,454,000 |
| 2021 | $-52,600,000 | $-60,251,000 |
| 2020 | $-33,809,000 | $-36,791,000 |
| 2019 | $-38,529,436 | $-38,539,436 |
| 2018 | $-32,146,057 | $-32,146,057 |
| 2017 | $-35,149,856 | $-21,968,614 |
| 2016 | $-14,733,780 | $-14,733,780 |
| 2015 | $-16,291,550 | $-16,291,550 |
| 2014 | $-8,609,575 | $-8,609,575 |